, /PRNewswire/ -- The global over-the-counter (OTC) analgesics market size is estimated to grow by .20 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 4.
98% during the forecast period. Growing aging population globally is driving market growth, with a trend towards growing number of launches of otc analgesics. However, growing number of product recalls poses a challenge.
Key market players include AKUMS, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cardinal Health Inc., Cipla Inc., CV Sciences Inc.
, Endo International Plc, GlaxoSmithKline Plc, Medterra CBD, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Piramal Enterprises Ltd.
, Reckitt Benckiser Group Plc, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd.
, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Weefsel Pharma.
Get a detailed analysis on regions, market segments, customer landscape, and companies- The OTC analgesics market is experiencing significant growth due to the increasing demand for effective and well-tolerated medications. Vendors are launching new products with regulatory approvals to expand their offerings and increase sales. Notable examples include GlaxoSmithKline's Voltaren Arthritis Pain and Perrigo Company PLC's acetaminophen and ibuprofen tablets.
Bayer's introduction of Iberogast, a plant-based digestive relief product, also highlights the market's expansion. These product launches and approvals ar.